Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: Retrospective assessment in 1470 patients

Holly L. Geyer, Robyn M. Scherber, Amylou Dueck, Jean Jacques Kiladjian, Zhijian Xiao, Stefanie Slot, Sonja Zweegman, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Konstanze Döhner, Claire N. Harrison, Deepti Radia, Pablo Muxi, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Bjorn Andreasson, Alessandro Rambaldi, Tiziano BarbuiAlessandro M. Vannucchi, Francesco Passamonti, Jan Samuelsson, Gunnar Birgegard, Ruben A. Mesa

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Symptom burden in myeloproliferative neoplasms (MPNs) is heterogeneous even among patients within the same MPN diagnosis. Using cluster analysis from prospectively gathered symptom burden data in 1470 international patients with essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF), we assessed for the presence of clusters and relationship to disease features and prognosis. In MF (4 clusters identified), clusters significantly differed by Dynamic International Prognostic Scoring System (DIPSS) risk (P < .001), leukopenia (P = .009), thrombocytopenia (P < .001), and spleen size (P = .02). Although an association existed between clusters and DIPSS risk, high symptom burden was noted in some low and intermediate-1-risk MF patients. In PV (5 clusters identified), total symptom score increased across clusters (P < .001), but clusters did not significantly differ by PV risk or the risk assessment variable of age. Among ET patients (5 clusters identified), clusters differed by gender (P = .04), anemia (P = .01), and prior hemorrhage (P = .047). Total symptom score increased across clusters (P < .001), but clusters did not significantly differ by International Prognostic Score for ET risk including the risk assessment variables. Significant symptom heterogeneity exists within each MPN subtype, sometimes independent of disease features or prognosis.

Original languageEnglish (US)
Pages (from-to)3803-3810
Number of pages8
JournalBlood
Volume123
Issue number24
DOIs
StatePublished - Jun 12 2014

Fingerprint

Cluster Analysis
Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Neoplasms
Risk assessment
Leukopenia
Cluster analysis
Thrombocytopenia
Anemia
Spleen
Hemorrhage

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients : Retrospective assessment in 1470 patients. / Geyer, Holly L.; Scherber, Robyn M.; Dueck, Amylou; Kiladjian, Jean Jacques; Xiao, Zhijian; Slot, Stefanie; Zweegman, Sonja; Sackmann, Federico; Fuentes, Ana Kerguelen; Hernández-Maraver, Dolores; Döhner, Konstanze; Harrison, Claire N.; Radia, Deepti; Muxi, Pablo; Besses, Carlos; Cervantes, Francisco; Johansson, Peter L.; Andreasson, Bjorn; Rambaldi, Alessandro; Barbui, Tiziano; Vannucchi, Alessandro M.; Passamonti, Francesco; Samuelsson, Jan; Birgegard, Gunnar; Mesa, Ruben A.

In: Blood, Vol. 123, No. 24, 12.06.2014, p. 3803-3810.

Research output: Contribution to journalArticle

Geyer, HL, Scherber, RM, Dueck, A, Kiladjian, JJ, Xiao, Z, Slot, S, Zweegman, S, Sackmann, F, Fuentes, AK, Hernández-Maraver, D, Döhner, K, Harrison, CN, Radia, D, Muxi, P, Besses, C, Cervantes, F, Johansson, PL, Andreasson, B, Rambaldi, A, Barbui, T, Vannucchi, AM, Passamonti, F, Samuelsson, J, Birgegard, G & Mesa, RA 2014, 'Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: Retrospective assessment in 1470 patients', Blood, vol. 123, no. 24, pp. 3803-3810. https://doi.org/10.1182/blood-2013-09-527903
Geyer, Holly L. ; Scherber, Robyn M. ; Dueck, Amylou ; Kiladjian, Jean Jacques ; Xiao, Zhijian ; Slot, Stefanie ; Zweegman, Sonja ; Sackmann, Federico ; Fuentes, Ana Kerguelen ; Hernández-Maraver, Dolores ; Döhner, Konstanze ; Harrison, Claire N. ; Radia, Deepti ; Muxi, Pablo ; Besses, Carlos ; Cervantes, Francisco ; Johansson, Peter L. ; Andreasson, Bjorn ; Rambaldi, Alessandro ; Barbui, Tiziano ; Vannucchi, Alessandro M. ; Passamonti, Francesco ; Samuelsson, Jan ; Birgegard, Gunnar ; Mesa, Ruben A. / Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients : Retrospective assessment in 1470 patients. In: Blood. 2014 ; Vol. 123, No. 24. pp. 3803-3810.
@article{f0f1ca3bc88e4fa2ba4d2d415201ae96,
title = "Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: Retrospective assessment in 1470 patients",
abstract = "Symptom burden in myeloproliferative neoplasms (MPNs) is heterogeneous even among patients within the same MPN diagnosis. Using cluster analysis from prospectively gathered symptom burden data in 1470 international patients with essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF), we assessed for the presence of clusters and relationship to disease features and prognosis. In MF (4 clusters identified), clusters significantly differed by Dynamic International Prognostic Scoring System (DIPSS) risk (P < .001), leukopenia (P = .009), thrombocytopenia (P < .001), and spleen size (P = .02). Although an association existed between clusters and DIPSS risk, high symptom burden was noted in some low and intermediate-1-risk MF patients. In PV (5 clusters identified), total symptom score increased across clusters (P < .001), but clusters did not significantly differ by PV risk or the risk assessment variable of age. Among ET patients (5 clusters identified), clusters differed by gender (P = .04), anemia (P = .01), and prior hemorrhage (P = .047). Total symptom score increased across clusters (P < .001), but clusters did not significantly differ by International Prognostic Score for ET risk including the risk assessment variables. Significant symptom heterogeneity exists within each MPN subtype, sometimes independent of disease features or prognosis.",
author = "Geyer, {Holly L.} and Scherber, {Robyn M.} and Amylou Dueck and Kiladjian, {Jean Jacques} and Zhijian Xiao and Stefanie Slot and Sonja Zweegman and Federico Sackmann and Fuentes, {Ana Kerguelen} and Dolores Hern{\'a}ndez-Maraver and Konstanze D{\"o}hner and Harrison, {Claire N.} and Deepti Radia and Pablo Muxi and Carlos Besses and Francisco Cervantes and Johansson, {Peter L.} and Bjorn Andreasson and Alessandro Rambaldi and Tiziano Barbui and Vannucchi, {Alessandro M.} and Francesco Passamonti and Jan Samuelsson and Gunnar Birgegard and Mesa, {Ruben A.}",
year = "2014",
month = "6",
day = "12",
doi = "10.1182/blood-2013-09-527903",
language = "English (US)",
volume = "123",
pages = "3803--3810",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients

T2 - Retrospective assessment in 1470 patients

AU - Geyer, Holly L.

AU - Scherber, Robyn M.

AU - Dueck, Amylou

AU - Kiladjian, Jean Jacques

AU - Xiao, Zhijian

AU - Slot, Stefanie

AU - Zweegman, Sonja

AU - Sackmann, Federico

AU - Fuentes, Ana Kerguelen

AU - Hernández-Maraver, Dolores

AU - Döhner, Konstanze

AU - Harrison, Claire N.

AU - Radia, Deepti

AU - Muxi, Pablo

AU - Besses, Carlos

AU - Cervantes, Francisco

AU - Johansson, Peter L.

AU - Andreasson, Bjorn

AU - Rambaldi, Alessandro

AU - Barbui, Tiziano

AU - Vannucchi, Alessandro M.

AU - Passamonti, Francesco

AU - Samuelsson, Jan

AU - Birgegard, Gunnar

AU - Mesa, Ruben A.

PY - 2014/6/12

Y1 - 2014/6/12

N2 - Symptom burden in myeloproliferative neoplasms (MPNs) is heterogeneous even among patients within the same MPN diagnosis. Using cluster analysis from prospectively gathered symptom burden data in 1470 international patients with essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF), we assessed for the presence of clusters and relationship to disease features and prognosis. In MF (4 clusters identified), clusters significantly differed by Dynamic International Prognostic Scoring System (DIPSS) risk (P < .001), leukopenia (P = .009), thrombocytopenia (P < .001), and spleen size (P = .02). Although an association existed between clusters and DIPSS risk, high symptom burden was noted in some low and intermediate-1-risk MF patients. In PV (5 clusters identified), total symptom score increased across clusters (P < .001), but clusters did not significantly differ by PV risk or the risk assessment variable of age. Among ET patients (5 clusters identified), clusters differed by gender (P = .04), anemia (P = .01), and prior hemorrhage (P = .047). Total symptom score increased across clusters (P < .001), but clusters did not significantly differ by International Prognostic Score for ET risk including the risk assessment variables. Significant symptom heterogeneity exists within each MPN subtype, sometimes independent of disease features or prognosis.

AB - Symptom burden in myeloproliferative neoplasms (MPNs) is heterogeneous even among patients within the same MPN diagnosis. Using cluster analysis from prospectively gathered symptom burden data in 1470 international patients with essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF), we assessed for the presence of clusters and relationship to disease features and prognosis. In MF (4 clusters identified), clusters significantly differed by Dynamic International Prognostic Scoring System (DIPSS) risk (P < .001), leukopenia (P = .009), thrombocytopenia (P < .001), and spleen size (P = .02). Although an association existed between clusters and DIPSS risk, high symptom burden was noted in some low and intermediate-1-risk MF patients. In PV (5 clusters identified), total symptom score increased across clusters (P < .001), but clusters did not significantly differ by PV risk or the risk assessment variable of age. Among ET patients (5 clusters identified), clusters differed by gender (P = .04), anemia (P = .01), and prior hemorrhage (P = .047). Total symptom score increased across clusters (P < .001), but clusters did not significantly differ by International Prognostic Score for ET risk including the risk assessment variables. Significant symptom heterogeneity exists within each MPN subtype, sometimes independent of disease features or prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84902595006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902595006&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-09-527903

DO - 10.1182/blood-2013-09-527903

M3 - Article

C2 - 24553173

AN - SCOPUS:84902595006

VL - 123

SP - 3803

EP - 3810

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -